We aimed to assess the safety and efficacy of lobeglitazone in patients with type 2 diabetes over 52 weeks through 28-week extension study. Clinical benefits in terms of glycemic and lipid control were maintained for 52 weeks. Lobeglitazone showed a favorable balance of efficacy and safety during the extension study.
- Clinical trial
- Randomised trial
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism